EP0341444A3
Rapid mutational analysis method
Abstract
A rapid mutational analysis method for mapping protein epitopes is disclosed. This method has been used to identify the binding sites for 16 anti-CD2 and anti-CD4 monoclonal antibodies. The powerful, rapid, and simple method of the present invention allows isolation of a very large number of mutants, and is applicable to any surface protein for which a cDNA and monoclonal antibodies are available. The present method is especially useful in ligand binding site studies for the design of new ligands and drugs.
Term
Term ended
Projected expiry passed 13 April 2009, 17.4 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 4 of 5
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EP0160486A2 | Cites | European Patent Office (EPO) | Search report |
| US4677056A | Cites | United States of America | Search report |
| US4677061A | Cites | United States of America | Search report |
| WO8604921A1 | Cites | World Intellectual Property Organization (WIPO) | Search report |
| CHEMICAL ABSTRACTS, Vol. 106, 1986, page 360, Ref. No. 3687x, Columbus, Ohio, US; J.S. McDOUGAL et al.: "Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4(T4) molecule: conformation dependence, epitope mapping, antibody inhibition and potential for idiotypic mimicry", & JOURNAL OF IMMUNOLOGY, 1986, 137 (9), 2937-44, whole Abstract. | Non-patent | – | Search report |
| PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE OF THE USA, Vol. 75, No. 6, June 1978, pages 2644-2648, Washington, D.C., US; L.J. WYSOCKI et al.: "Planning for lymphocytes: A method for cell selection", page 2645, column 1, lines 10-39. | Non-patent | – | Search report |
| CELL, Vol. 50, September 11, 1987, pages 975-985, Boston, MA, US; L.A. LASKY et al.: "Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor", whole article. | Non-patent | – | Search report |
| JOURNAL OF NEUROSCIENCE RESEARCH, Vol. 18, 1987, pages 102-107, Alan R. Liss, Inc., New York, US; P. SACERDOTE et al.: "Vasoactive intestinal peptide 1-12: A ligand for the CD4 (T4)/human immunodeficiency virus receptor", whole article. | Non-patent | – | Search report |
17 members in 8 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 181826 | United States of America | – | |
| 18182688 | United States of America | A | |
| US19880181826 | – | – | – |
Members17
| Document | Office | Kind | |
|---|---|---|---|
| DK172589D0 | Denmark | D0 | |
| PT90265A | Portugal | A | |
| EP0341444A2 | European Patent Office (EPO) | A2 | |
| DK172589A | Denmark | A | |
| JPH02203787A | Japan | A | |
| EP0341444A3This record | European Patent Office (EPO) | A3 | |
| PT90265B | Portugal | B | |
| EP0341444B1 | European Patent Office (EPO) | B1 | |
| AT114821T | Austria | T | |
| ATE114821T1 | Austria | T1 | |
| DE68919524D1 | Germany | D1 | |
| ES2065933T3 | Spain | T3 | |
| US5411861A | United States of America | A | |
| DE68919524T2 | Germany | T2 | |
| DK172110B1 | Denmark | B1 | |
| US5955264A | United States of America | A | |
| US6579676B1 | United States of America | B1 |
51 legal events, as 6 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Be: lapsedLapsedBERE | BERE | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Notification of lapseLapsedST | ST | FR | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Validation in greece3014502FG4A | FG4A | GR | |
| Fr: translation filedET | ET | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0341444
- Publication, DOCDB
- 0341444
- Publication, EPODOC
- EP0341444
- Application
- 106627
- Application, DOCDB
- 89106627
- Application, EPODOC
- EP19890106627
Titles3
- English
- RAPID MUTATIONAL ANALYSIS METHOD
- German
- Schnelles Verfahren zur Analyse von Mutationen
- French
- Méthode d'analyse rapide de mutation
Classification
- CPC, 6
- C12N15/1086
- C07K14/70514
- C12N15/1034
- G01N33/56972
- G01N33/56988
- G01N33/6878
- IPC, 15
- G01N33 53
- C07K7 08
- C07K14 00
- C07K14 435
- C07K14 705
- C07K14 73
- C12N5 10
- C12N7 04
- C12N15 09
- C12N15 10
- C12P21 02
- C12R1 91
- G01N33 569
- G01N33 577
- G01N33 68
Designated states1
- Contracting states, 1
- Sweden